RE: The Tesla and Amazon comparison to hemo22 Nov 2024 16:46
JHFH - yes it raises questions but having only 2.5m shares in issue is unheard of in small pharma and yet to dose a patient. That could quickly become 3.75m if they decide to issue the 50% in one ago (unlikely I know) - that is a large dilution for current holders. Also, what about this statement from the half year report that many on here were taking as set in stone :
"We are confident in our ability to finance their development through a combination of equity capital, industry partnerships, and non-dilutive funding"
Seems to have been brushed under the table